IP Library Granted Patent US 9,669,011
Granted Patent B2
US 9,669,011 · App. 14/841,001 · Granted Jun 6, 2017

Methods of use of cyclopamine analogs

Inventors: Alfredo C. Castro (Winchester, MA); Michael J. Grogan (Winchester, MA); Karen J. McGovern (Groton, MA); Martin R. Tremblay (Melrose, MA)
Assignee: Infinity Pharmaceuticals, Inc.
A61K31/4355A61K9/0014A61K31/17A61K31/196A61K31/198A61K31/454A61K31/4745A61K31/519A61K31/56A61K31/573A61K31/58A61K31/664A61K31/69A61K31/704A61K31/7068A61K31/7076A61K38/21A61K45/06A61N5/10C07D307/94C07D471/04C07D471/10C07D491/04C07D491/048C07D491/10C07D491/107C07J69/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,669,011
App. No.
14/841,001
Granted
Jun 6, 2017
Kind
B2
Abstract

The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:

Claims (14)

1. A method for treating cancer in a subject, the method comprising administering to the subject a composition comprising a compound having the structure:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

2. The method of claim 1 , wherein the compound is in the form of a pharmaceutically acceptable salt.

3. The method of claim 2 , wherein the salt is an acid salt.

4. The method of claim 3 , wherein the salt is an inorganic acid salt.

5. The method of claim 3 , wherein the salt is a hydrochloric acid salt.

6. The method of claim 1 , wherein the composition is a liquid composition.

7. The method of claim 1 , wherein the cancer is a cancer of the skin.

8. The method of claim 7 , wherein the composition is in the form of a cream, ointment, or spray.

9. The method of claim 7 , wherein the cancer is selected from the group consisting of squamous cell carcinoma, basal cell carcinoma, and melanoma.

10. The method of claim 9 , wherein the cancer is basal cell carcinoma.

11. The method of claim 7 , wherein the composition is administered topically.

12. The method of claim 1 , wherein said administering is carried out in combination with an additional cancer treatment.

13. The method of claim 12 , wherein said additional cancer treatment comprises radiation, surgery, or administration of a second chemotherapeutic agent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2020
From: INFINITY PHARMACEUTICALS, INC.
To: ROYALTY SECURITY, LLC
Reel/Frame 051519/0511 →
CONFIRMATORY LICENSE Recorded Dec 7, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044753/0341 →
Continuity (7)
Continuation 14054350 · Oct 15, 2013
Continuation 13475510 · May 18, 2012
Continuation 13090694 · Apr 20, 2011
Continuation 11965675 · Dec 27, 2007
Provisional Application 60941596 · Jun 1, 2007
Provisional Application 60878018 · Dec 28, 2006
Related Publication 20160158208A1 · Jun 9, 2016